13.72

8.04% -1.20

Promis Neurosciences Inc (PMN)

Overview News Price History Financials Discussions Forecast Stock Split

Promis Neurosciences Inc stock is traded at $13.72, with a volume of 33,785. It is down -8.04% in the last 24 hours and up +4.26% over the past month. ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Previous Close:

$14.92

Open:

$14.68

24h Volume:

33,785

Relative Volume:

0.49

Market Cap:

$123.04M

Revenue:

Net Income/Loss:

$-40.62M

P/E Ratio:

-0.7069

EPS:

-19.4076

Net Cash Flow:

$-35.63M

1W Performance:

+12.46%

1M Performance:

+4.26%

6M Performance:

-3.11%

1Y Performance:

-28.83%

1-Day Range:

$13.47

$14.93

1-Week Range:

$11.25

$17.25

52-Week Range:

$6.27

$27.40

Promis Neurosciences Inc Stock (PMN) Company Profile

Name

Promis Neurosciences Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

416-847-6898

Address

SUITE 200, 1920 YONGE STREET, TORONTO

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

PMN's Discussions on Twitter

Compare PMN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMN Promis Neurosciences Inc	13.72	105.10M	0	-40.62M	-35.63M	-19.41
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Promis Neurosciences Inc Stock (PMN) Latest News

Jul 28, 2026

PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus

Jul 28, 2026

Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada

Jul 28, 2026

Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com

Jul 28, 2026

Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada

Jul 28, 2026

ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus

Jul 28, 2026

ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus

Jul 28, 2026

ProMIS Neurosciences Inc. Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in PRECISE-AD Phase 1b Alzheimer?s Disease Trial - marketscreener.com

Jul 28, 2026

ProMIS Neurosciences stock jumps on trial safety data - Investing.com

Jul 28, 2026

ProMIS Reports Positive Interim PMN310 Alzheimer’s Trial Data - TipRanks

Jul 28, 2026

ProMIS Neurosciences reports no ARIA‑E and favorable 6‑month biomarker trends for PMN310; 12‑month topline due Q1 2027 - TradingView

Jul 28, 2026

ProMIS Neurosciences (Nasdaq: PMN) reports positive six-month PMN310 Alzheimer’s trial data - Stock Titan

Jul 28, 2026

ProMIS Neurosciences Reports Positive Blinded Six-Month - GlobeNewswire

Jul 28, 2026